Praxis Precision Medicines announced detailed launch plans for relutrigine and ulixacaltamide, targeting FDA action dates in late 2026 and early 2027. These drugs address rare epilepsies and essential tremor, with relutrigine showing strong seizure reduction and ulixacaltamide demonstrating durable efficacy. The company also revealed plans to expand ulixacaltamide into Parkinson’s, restless legs syndrome, and autism, plus new pain and epilepsy drug candidates. These developments position Praxis as a leading CNS biotech with multiple late-stage assets and a broad pipeline for neurological disorders.
Praxis Precision Medicines' pipeline update provides context for the health sector's performance on Pluang. Of 150 priced US health stocks, 23 rose and 124 fell today. Notable movers include IBRX at USD 6.06 with a 9.15% decline and 98% sell activity, BNGO at USD 1.00 down 9.09%, and FLNA at USD 0.44 down 8.71% with 87% buy activity, as of Nov 13, 2026 04:11 WIB.
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
